<DOC>
	<DOCNO>NCT00651209</DOCNO>
	<brief_summary>This study evaluate use telbivudine patient HBeAg-positive CHB option intensify treatment Week 24 add tenofovir patient achieve HBV DNA non-detectability .</brief_summary>
	<brief_title>A Single-arm Study Evaluating Efficacy Safety Telbivudine With Without add-on Tenofovir Adults With HBeAg-positive Chronic Hepatitis B ( CHB )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Inclusion criterion Male female , least 18 year age . Documented HBeAg positive CHB define follow : Clinical history compatible CHB Detectable serum HBsAg Screening visit least 6 month prior HBeAg positive Screening visit HBeAb negative Screening visit Serum HBV DNA level ≥ 5 log10 copies/mL , determine COBAS Amplicor HBV PCR assay ( LLOD = 300 copy / mL ) central study laboratory Screening visit Evidence chronic liver inflammation , document previous history elevate serum ALT /or AST level ( least two elevated ALT AST value span six month , document available record ) without prior liver biopsy consistent CHB For patient cirrhosis , clinical history compatible compensate liver disease Elevated serum ALT level ( 1.3 10 x ULN ) Screening visit Patient willing able comply study drug regimen study requirement . The patient willing able provide write informed consent participate study . Exclusion criteria Patients exclude study follow : History hypersensitivity study drug drug similar chemical structure . Patient pregnant breastfeeding . Women childbearing potential ( WOCBP ) , define woman physiologically capable become pregnant , include woman whose career , lifestyle , sexual orientation precludes intercourse male partner woman whose partner sterilize vasectomy mean . The exception aforementioned criterion give meet follow definition postmenopausal : 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/ml ( IU/L ) 6 week post surgical bilateral oophorectomy without hysterectomy surgically sterilize ( e.g. , bilateral tubal ligation ) patient must agree use two method birth control . This combination hormonal contraception ( implantable , patch , oral injection ) , IUD , male female condom spermicidal gel , diaphragm , sponge cervical cap . Women childbearing potential must negative serum betahuman chorionic gonadotropin ( βHCG ) Screening . Is male capable reproduction , define men physiologically capable produce sperm , include men whose career , lifestyle , sexual orientation precludes intercourse female partner men sterilize ( vasectomy ) whose partner sterilize surgical bilateral oophorectomy without hysterectomy , bilateral tubal ligation mean , UNLESS female partner meet follow definition postmenopausal : 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/ml ( IU/L ) patient must agree use two method birth control . This combination hormonal contraception ( implantable , patch , oral injection ) , IUD , male female condom spermicidal gel , diaphragm , sponge cervical cap . Patient coinfected HCV , HDV , HIV . Patients previously involve trial telbivudine . Patient receive nucleoside nucleotide drug whether approve investigational time . Patient receive IFN immunomodulatory treatment 12 month Screening study . Patient history clinical signs/symptoms hepatic decompensation ascites , esophageal variceal bleeding , hepatic encephalopathy , hepatorenal syndrome , hepatic hydrothorax , hepatopulmonary syndrome spontaneous bacterial peritonitis . Patient medical condition require prolonged frequent use systemic acyclovir famciclovir . History malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin . Patients previous finding suggestive possible HCC , disease rule prior entrance study . Patient one additional know primary secondary cause liver disease , CHB , include steatohepatitis autoimmune hepatitis among liver disease . Note : Gilbert 's syndrome DubinJohnson syndrome consider exclusion criterion study . History acute chronic medical condition opinion investigator would make patient unsuitable inclusion study . Patient currently abuse alcohol illicit drug , history alcohol abuse illicit substance abuse within precede two year . Please refer Appendix 3 . Patient medical condition require frequent prolong use systemic corticosteroid , although topical inhaled corticosteroid allow . Patient history clinical laboratory evidence chronic renal insufficiency define estimate serum creatinine clearance &lt; 50 mL/min use CockcroftGault method . Patient medical condition require chronic prolong use potentially hepatotoxic drug nephrotoxic drug . Patient concurrent medical social condition likely preclude compliance schedule evaluation protocol , likely confound efficacy safety observation study . Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer . Patient history myopathy , myositis , persistent muscle weakness . Patient follow laboratory value Screening : Hemoglobin &lt; 11 g/dL ( 110 g/L ) men &lt; 10 g/dL ( 100 g/L ) woman Total WBC &lt; 3,500/mm3 ( 3.5 x 109/Liter ) Absolute neutrophil count ( ANC ) &lt; 1,500/mm3 ( 1.5 x 109/Liter ) Platelet count &lt; 75,000/mm3 ( 75 x 109/Liter ) Serum amylases lipase ≥ 1.5 x ULN Serum albumin &lt; 3.3 g/dL ( 33g/L ) Total bilirubin ≥ 2.0 mg/dL ( 34.2 µmol/L ) Estimated calculated serum creatinine clearance &lt; 50 mL/min ( 0.48 ml/s ) use CockcroftGault method lean ideal body weight ; see Glossary Terms ( Cockcroft 1976 ) AFP &gt; 50 ng/mL µg/L ( require work per local medical standard )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hepatitis B , chronic</keyword>
	<keyword>Telbivudine</keyword>
	<keyword>Tenofovir</keyword>
	<keyword>Roadmap Concept</keyword>
</DOC>